OBJECTIVES: Malignant pleural mesothelioma (MPM) remains an aggressive thoracic malignancy associated with poor prognosis. There is no standard treatment regimen, and particularly, the impact of radical surgery remains controversial. The main goal of our retrospective single-centre study was to evaluate the surgical and non-surgical treatment modalities applied at our division regarding their effect on the patient's survival. METHODS: During the last decade, 82 patients with histologically confirmed MPM were treated at our division. The complete clinical records of 61 patients were eligible for statistical evaluation. RESULTS: There were 14 women (23%) and 47 men (77%) with a mean age of 63.7 years. Epitheloid subtype was found in 48 patients (78.7%), sarcomatoid in 3 (4.9%) and biphasic in 10 (16%). Surgery as the first treatment modality was performed in 44 patients (72.1%). Pleurectomy/decortication was done in 28 cases (45.9%), extended pleurectomy/decortication was performed in 13 (21.3%) and extrapleural pneumonectomy in 3 (4.9%). Additional intraoperative photodynamic therapy was administered in 20 patients, 34 underwent chemotherapy (55.7%) and 12 had radiotherapy (19.7%). Mean survival time for the collective was 18.3 months. Five-year survival was 17% in the epitheloid histology group, where patients treated with chemotherapy alone yielded a significant increase in survival (P = 0.049), and those with other subtypes survived for a maximum of 20.6 months. CONCLUSIONS: Chemotherapy and pleurectomy/decortication can extend the survival time of patients with MPM remarkably. The adequate treatment options have to be tailored to the specific particular needs of each patient considering histological subtype, tumour stage and patient's individual functional assessment as well as comorbidity.
OBJECTIVES:Malignant pleural mesothelioma (MPM) remains an aggressive thoracic malignancy associated with poor prognosis. There is no standard treatment regimen, and particularly, the impact of radical surgery remains controversial. The main goal of our retrospective single-centre study was to evaluate the surgical and non-surgical treatment modalities applied at our division regarding their effect on the patient's survival. METHODS: During the last decade, 82 patients with histologically confirmed MPM were treated at our division. The complete clinical records of 61 patients were eligible for statistical evaluation. RESULTS: There were 14 women (23%) and 47 men (77%) with a mean age of 63.7 years. Epitheloid subtype was found in 48 patients (78.7%), sarcomatoid in 3 (4.9%) and biphasic in 10 (16%). Surgery as the first treatment modality was performed in 44 patients (72.1%). Pleurectomy/decortication was done in 28 cases (45.9%), extended pleurectomy/decortication was performed in 13 (21.3%) and extrapleural pneumonectomy in 3 (4.9%). Additional intraoperative photodynamic therapy was administered in 20 patients, 34 underwent chemotherapy (55.7%) and 12 had radiotherapy (19.7%). Mean survival time for the collective was 18.3 months. Five-year survival was 17% in the epitheloid histology group, where patients treated with chemotherapy alone yielded a significant increase in survival (P = 0.049), and those with other subtypes survived for a maximum of 20.6 months. CONCLUSIONS: Chemotherapy and pleurectomy/decortication can extend the survival time of patients with MPM remarkably. The adequate treatment options have to be tailored to the specific particular needs of each patient considering histological subtype, tumour stage and patient's individual functional assessment as well as comorbidity.
Authors: Tristan D Yan; Michael Boyer; Mo Mo Tin; Junyang Sim; Catherine Kennedy; Jocelyn McLean; Paul G Bannon; Brian C McCaughan Journal: Ann Thorac Surg Date: 2009-05 Impact factor: 4.330
Authors: Servet Bölükbas; Christian Manegold; Michael Eberlein; Thomas Bergmann; Annette Fisseler-Eckhoff; Joachim Schirren Journal: Lung Cancer Date: 2009-09-17 Impact factor: 5.705
Authors: P E Van Schil; P Baas; R Gaafar; A P Maat; M Van de Pol; B Hasan; H M Klomp; A M Abdelrahman; J Welch; J P van Meerbeeck Journal: Eur Respir J Date: 2010-06-04 Impact factor: 16.671
Authors: Gordon Buduhan; Shekhar Menon; Ralph Aye; Brian Louie; Vivek Mehta; Eric Vallières Journal: Ann Thorac Surg Date: 2009-09 Impact factor: 4.330
Authors: Apostolos Nakas; Delphine Sophie Trousse; Antonio E Martin-Ucar; David A Waller Journal: Eur J Cardiothorac Surg Date: 2008-07-24 Impact factor: 4.191
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Mehmet Ali Bedirhan; Levent Cansever; Adalet Demir; Süleyman Ceyhan; Hasan Akın; Halide Nur Urer; Aysun Olçmen; Celalettin Kocatürk; Ibrahim Dinçer Journal: J Thorac Dis Date: 2013-08 Impact factor: 2.895
Authors: Alfonso Fiorelli; Francesca Pentimalli; Vittorio D'Urso; Domenico Di Marzo; Iris Maria Forte; Antonio Giordano; Marina Di Domenico; Marina Accardo; Umberto Di Serio; Mario Santini Journal: Eur J Cardiothorac Surg Date: 2014-01-06 Impact factor: 4.191